Clinical trials: Secondary Hemophagocytic Lymphohistiocytosis
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis
- Trial name
- NCT04979884
- Testing
- cyclosporine
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
COVID
Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH
SARS-CoV2 has become a pandemic disease putting an enormous burden on health care systems around the world. A considerable amount of patients require intensive care treatment for Covid-19 associated pneumonia.
- Trial name
- COVIDHLH (NCT04347460)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Technical University of Munich
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal.
- Conditions
- Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
- Trial name
- NCT06339177
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks.
- Trial name
- NCT07270835
- Testing
- Rituximab, Zanubrutinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic…
- Trial name
- NCT05841342
- Testing
- No intervention
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic Lymphohistiocytosis
Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH)
Rationale/Gaps in Existing Knowledge: Therapy of Infection-associated Secondary Hemophagocytic lymphohistiocytosis (sHLH) in adult lacks evidence from randomized trial guiding first-line immunomodulation and current therapeutic…
- Trial name
- isHLH-IVD/IVIg (NCT07861776)
- Testing
- Intravenous Immunoglobulin (IVIg) therapy, Intravenous Dexamethasone (IVD) therapy, Targeted antimicrobial therapy & standard care
- Volunteers
- 116 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hemophagocytic Lymphohistiocytosis
Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
The investigators would like to propose a pilot study evaluating the efficacy of etoposide combined with immunosuppressive agents for adult secondary hemophagocytic lymphohistiocytosis (HLH), in order to prove out whether the…
- Trial name
- HELA2012 (NCT01547143)
- Testing
- IST and/or alloHCT
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Asan Medical Center
Adult Refractory Secondary Hemophagocytic Lymphohistiocytosis, Secondary Hemophagocytic Lymphohistiocytosis
Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis
The goal of this observational study is to learn if interferon-gamma monoclonal antibody combined with dexamethasone works to treat adults with refractory secondary hemophagocytic lymphohistiocytosis (HLH).
- Conditions
- Adult Refractory Secondary Hemophagocytic Lymphohistiocytosis, Secondary Hemophagocytic Lymphohistiocytosis, HLH
- Trial name
- NCT07531069
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fudan University
Hemophagocytic Syndrome (HPS)
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
This is a pilot study to determine the efficacy of Ruxolitinib in secondary hemophagocytic syndrome. The primary objective is to assess the efficacy of ruxolitinib 15 mg PO twice daily in patients with HPS.
- Trial name
- NCT02400463
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan Rogel Cancer Center
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset…
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Trial name
- NCT03311854
- Testing
- Emapalumab
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- Swedish Orphan Biovitrum
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically…
- Trial name
- NCT05416307
- Testing
- ELA026
- Where
- 42 sites in United States, Austria and 5 more
- Volunteers
- 156 people
- Sponsor
- Electra Therapeutics Inc.
Hemophagocytic Lymphohistiocytosis
Ruxolitinib Combined With Dexamethasone for HLH
A protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.
- Trial name
- NCT03795909
- Testing
- Ruxolitinib, Dexamethasone
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Capital Research Institute of Pediatrics
Hemophagocytic Lymphohisticytosis
Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity
Hemophagocytic lymphohisticytosis (HLH) is a rare and severe disease of genetic origin in children (familial-HLH, F-HLH) or affecting adults secondary to infections, hematologic malignancies or auto-immune diseases…
- Trial name
- NCT01125319
- Testing
- blood sample
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Rituximab Monotherapy for EBV-HLH and CAEBV
This study is a prospective single-arm clinical study, focusing on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection with only and mainly B lymphocytes of EBV…
- Trial name
- NCT05384743
- Testing
- Rituximab Monotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytosis (HLH)
Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory complication that can occur after allogeneic hematopoietic stem cell transplantation.
- Trial name
- HSCT-HLH (NCT07905066)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Peking University People's Hospital